- Home
- SLNO vs MLYS Comparison
SLNO vs MLYS Comparison
Compare SLNO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- MLYS
- Stock Information
- Founded
- SLNO 1999
- MLYS 2019
- Country
- SLNO United States
- MLYS United States
- Employees
- SLNO N/A
- MLYS N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SLNO Health Care
- MLYS Health Care
- Exchange
- SLNO Nasdaq
- MLYS Nasdaq
- Market Cap
- SLNO 3.8B
- MLYS 3.1B
- IPO Year
- SLNO 2014
- MLYS 2023
- Fundamental
- Price
- SLNO $62.37
- MLYS $37.06
- Analyst Decision
- SLNO Strong Buy
- MLYS Strong Buy
- Analyst Count
- SLNO 9
- MLYS 6
- Target Price
- SLNO $116.78
- MLYS $42.60
- AVG Volume (30 Days)
- SLNO 2.7M
- MLYS 1.5M
- Earning Date
- SLNO 11-05-2025
- MLYS 11-10-2025
- Dividend Yield
- SLNO N/A
- MLYS N/A
- EPS Growth
- SLNO N/A
- MLYS N/A
- EPS
- SLNO N/A
- MLYS N/A
- Revenue
- SLNO $32,656,999.00
- MLYS N/A
- Revenue This Year
- SLNO N/A
- MLYS N/A
- Revenue Next Year
- SLNO $181.85
- MLYS N/A
- P/E Ratio
- SLNO N/A
- MLYS N/A
- Revenue Growth
- SLNO N/A
- MLYS N/A
- 52 Week Low
- SLNO $41.50
- MLYS $8.24
- 52 Week High
- SLNO $90.32
- MLYS $41.09
- Technical
- Relative Strength Index (RSI)
- SLNO 48.83
- MLYS 62.03
- Support Level
- SLNO $55.78
- MLYS $37.48
- Resistance Level
- SLNO $68.46
- MLYS $40.91
- Average True Range (ATR)
- SLNO 4.12
- MLYS 2.15
- MACD
- SLNO 0.71
- MLYS -0.90
- Stochastic Oscillator
- SLNO 67.58
- MLYS 25.89
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.